MedPath
FDA Approval

CAPLYTA

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
June 29, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Lumateperone(42 mg in 1 1)

Products3

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

CAPLYTA

Product Details

NDC Product Code
72060-142
Application Number
NDA209500
Marketing Category
NDA (C73594)
Route of Administration
ORAL
Effective Date
September 22, 2022
Code: 70BSQ12069Class: ACTIBQuantity: 42 mg in 1 1
MANNITOLInactive
Code: 3OWL53L36AClass: IACT
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48Class: IACT
GELATINInactive
Code: 2G86QN327LClass: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
TALCInactive
Code: 7SEV7J4R1UClass: IACT

CAPLYTA

Product Details

NDC Product Code
72060-110
Application Number
NDA209500
Marketing Category
NDA (C73594)
Route of Administration
ORAL
Effective Date
September 22, 2022
Code: 70BSQ12069Class: ACTIBQuantity: 10.5 mg in 1 1

CAPLYTA

Product Details

NDC Product Code
72060-121
Application Number
NDA209500
Marketing Category
NDA (C73594)
Route of Administration
ORAL
Effective Date
September 22, 2022
Code: 70BSQ12069Class: ACTIBQuantity: 21 mg in 1 1
© Copyright 2025. All Rights Reserved by MedPath